Understanding Muscular Dystrophy: An Introduction to the Genetic Disorder

Millions of people around the world live with a condition that quietly steals their strength – not because of injury or inactivity, but because of something written into their DNA. Muscular dystrophy (MD) is that condition. It is not a single disease but a group of over 40 distinct genetic disorders, each affecting the muscles in its own way, at its own pace, and with its own level of severity. For educators, caregivers, students, and anyone working in disability support, understanding what muscular dystrophy is – and why it happens – is the first step toward providing meaningful, informed support.

What is muscular dystrophy? 🔗

At its most basic level, muscular dystrophy is a condition in which the body cannot properly maintain healthy muscle tissue. According to the National Institute of Neurological Disorders and Stroke (NINDS), MD refers to a group of genetic diseases that cause progressive weakness and degeneration of skeletal muscles. The word “progressive” is important here – unlike a muscle injury that heals over time, MD gets worse, not better. Muscles gradually break down, lose their strength, and shrink. In many cases, the person eventually loses the ability to walk or perform basic daily tasks independently.

What makes MD particularly complex is its sheer variety. There are more than 30 types of muscular dystrophy, and no two are exactly alike. They differ in the age at which symptoms appear, which muscle groups are affected first, how quickly the condition worsens, and what other body systems may be involved. Some forms appear in infancy; others may not surface until adulthood. Some progress rapidly; others remain relatively stable for years. Even two people with the same type of MD may have very different experiences.

It is also important to note that MD is not contagious. It cannot be caused by injury, physical activity, or exposure to another person. It is entirely rooted in genetics.

The genetic basis of muscular dystrophy 🔗

To understand why MD happens, it helps to understand what muscles need in order to stay healthy. Muscles are made up of thousands of fibers, and those fibers depend on specific proteins to keep them strong and structurally intact. The most well-known of these proteins is dystrophin. As explained by the NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), dystrophin helps strengthen muscle fibers and protect them from injury as muscles contract and relax. When the gene responsible for producing dystrophin is mutated, the body either produces a faulty version of the protein or none at all. Without sufficient dystrophin, muscle cells are easily damaged and, over time, cannot repair themselves – leading to progressive muscle loss.

Across different types of MD, different genes and proteins are involved, but the outcome is consistently the same: muscle fibers break down faster than the body can replace them. Healthy muscle tissue may eventually be replaced by fibrous tissue and fat, making it impossible to generate normal muscular force.

How is MD inherited? 🔗

MD can be passed down through families or arise spontaneously. The Centers for Disease Control and Prevention (CDC) notes that MD can run in families, or a person can be the first in their family to have it. There are three main inheritance patterns:

X-linked recessive is the most common pattern for several types of MD, including Duchenne and Becker MD. Because the genetic mutation sits on the X chromosome, males – who have only one X chromosome – are far more likely to be affected. Females typically carry the mutation without showing full symptoms, though some female carriers can experience mild muscle weakness. As clarified by MedlinePlus Genetics, a father cannot pass an X-linked trait to his sons; in most cases, an affected male inherits the mutation from his mother.

Autosomal dominant inheritance means a child can develop MD by inheriting just one mutated gene from either parent. In this pattern, males and females are equally at risk.

Autosomal recessive inheritance requires a child to inherit two mutated copies of the gene – one from each parent – to develop the condition. A person who inherits only one copy is considered a carrier and typically does not show symptoms.

In a smaller number of cases, the genetic mutation occurs spontaneously – meaning no family history is present. This is sometimes called a de novo mutation, where the change arises during early development without being passed down.

Major types of muscular dystrophy 🔗

While all forms of MD share the feature of progressive muscle weakness, each type has distinct characteristics. The CDC provides an overview of the most recognised types, some of which are described below.

Duchenne muscular dystrophy (DMD) 🔗

DMD is the most common and most severe form of MD. It almost exclusively affects males and typically appears before the age of five. Children with DMD may experience frequent falls, difficulty rising from the floor, a waddling walk, and delayed motor development. According to the Johns Hopkins Medicine, DMD generally causes immobility by ages 10-12, along with cardiomyopathy due to weakened heart muscles. Without dystrophin, muscles scar, inflame, and gradually waste away. Males with DMD typically live into their twenties, though advances in care are slowly improving those numbers.

Becker muscular dystrophy (BMD) 🔗

BMD is caused by mutations in the same gene as DMD, but the resulting dystrophin protein, though abnormal, is at least partially functional. This makes BMD considerably milder and slower in progression. Symptoms often appear in the teens or early adulthood, and some individuals live into their forties or beyond. BMD primarily affects males, just like DMD, and can also involve cardiac complications.

Myotonic dystrophy 🔗

Myotonic dystrophy is notable for an unusual symptom: the inability to relax muscles after contraction. A person may have difficulty releasing a handshake, for example. It is caused by abnormal repetition of certain DNA sequences – while most people have around 40 repeats of a particular genetic code, those with myotonic MD may have 4,000 or more repeats, which interferes with normal muscle protein production. Both males and females are equally affected, and symptoms typically begin between ages 20 and 30, though they can appear as early as birth.

Facioscapulohumeral muscular dystrophy (FSHD) 🔗

FSHD affects the muscles of the face, shoulders, and upper arms. Symptoms usually begin in young adulthood. It affects males and females equally, and most people with FSHD have a near-normal life expectancy, though they may experience significant limitations in mobility and arm function over time.

Limb-girdle muscular dystrophy (LGMD) 🔗

LGMD causes weakness primarily in the muscles around the hips and shoulders. It affects males and females equally, and onset can range from childhood to adulthood depending on the specific subtype. The heart, spine, and hips can also be affected.

Congenital muscular dystrophy (CMD) 🔗

CMD is present from birth or early infancy. Infants with CMD typically show significant muscle weakness from the start and may never be able to sit or stand without support. In some cases, brain development is also affected, leading to vision or speech problems.

How does MD affect the body beyond muscles? 🔗

MD is often thought of as a condition that only affects skeletal muscles, but several types extend their reach to other organ systems. The heart, for instance, is a muscle – and in conditions like DMD and Becker MD, cardiomyopathy typically begins in adolescence and can become life-threatening as it progresses. Respiratory muscles are also at risk, particularly in DMD, where diaphragm weakness can eventually lead to respiratory failure – one of the leading causes of death in affected individuals.

Some types of MD can affect the brain. Children with DMD, for example, may have higher rates of autism spectrum disorder, ADHD, obsessive compulsive disorder, and anxiety compared to those without the condition, as noted by the Mayo Clinic. Bone health can also be compromised, particularly in wheelchair users, due to reduced weight-bearing activity leading to lower bone density and an increased fracture risk.

Diagnosis: how is MD identified? 🔗

Diagnosing MD can be challenging because many of its symptoms overlap with other neuromuscular conditions. According to StatPearls (NIH), muscular dystrophy has a global incidence of approximately 1 in 5,000 individuals and is most commonly diagnosed in childhood. Diagnosis typically involves a combination of blood tests to detect elevated creatine kinase levels (an enzyme released by damaged muscle cells), genetic testing to identify specific mutations, electromyography (EMG), and in some cases, a muscle biopsy. Genetic testing has become increasingly central to diagnosis, as it can identify the precise mutation causing the disorder and guide treatment decisions.

Early diagnosis is considered critical. While it cannot prevent the disease, it allows families to begin appropriate therapy sooner, make informed decisions about care, and access genetic counselling to understand the risk for other family members.

Is there a cure? Current treatment and management 🔗

There is currently no cure for any form of muscular dystrophy. However, this does not mean treatment options are absent – in fact, the landscape of MD management has expanded significantly, especially for Duchenne MD. Management broadly falls into two categories: slowing disease progression and managing symptoms to improve quality of life.

Corticosteroids and standard medical therapy 🔗

Corticosteroids such as prednisone and deflazacort have long been the standard pharmacological treatment for DMD. They work by reducing muscle inflammation, helping to maintain muscle strength for longer. A newer option, vamorolone, was approved by the FDA in October 2023 for DMD patients aged two and older. It offers similar efficacy to prednisone but with a better safety profile – importantly, without the bone-thinning and growth-stunting side effects associated with long-term corticosteroid use, as noted in a peer-reviewed analysis in Therapeutic Advances in Neurological Disorders.

Gene therapy: a new frontier 🔗

Among the most exciting recent developments is the emergence of gene therapy for DMD. In 2024, the FDA expanded its approval of Elevidys (delandistrogene moxeparvovec), a gene therapy for both ambulatory and non-ambulatory individuals aged four and older with a confirmed DMD gene mutation. Elevidys works by delivering a smaller, functional version of the dystrophin gene – called micro-dystrophin – directly to skeletal and heart muscles. While it is not a cure, and long-term durability is still being studied, it represents a significant shift from treating symptoms to addressing the underlying genetic cause.

In March 2024, the FDA also approved givinostat (Duvyzat), an oral treatment for DMD patients aged six and older, regardless of their specific genetic mutation – making it the first non-steroidal DMD treatment approved for broad use. According to the Muscular Dystrophy Association (MDA), givinostat reduces inflammation and slows muscle degeneration by targeting specific biological pathways involved in muscle damage.

Physical, occupational, and respiratory therapy 🔗

Beyond medication, supportive therapies play a central role in managing MD. Physical therapy helps maintain range of motion and delay contractures – the tightening of muscles and tendons that limits movement. Occupational therapy supports independence in daily tasks. Respiratory therapy and assisted ventilation become essential as breathing muscles weaken in advanced cases. Speech therapy may be needed for those with swallowing difficulties. Orthotic devices and, in some cases, corrective surgery can help maintain mobility for longer.

Genetic counselling 🔗

For families affected by MD, genetic counselling is a vital resource. It helps family members understand their risk of carrying or passing on a mutation, informs family planning decisions, and supports the psychological adjustment to a hereditary diagnosis. As noted by StatPearls, in X-linked recessive forms, male siblings of an affected individual have a 50% chance of being affected, while female siblings have a 50% chance of being carriers – making counselling for the wider family an important step.

Living with muscular dystrophy 🔗

A diagnosis of MD – whether for oneself or a family member – is life-changing. But it is not the end of meaningful participation in life, education, or work. Many individuals with MD, particularly those with milder forms like FSHD or Becker MD, live full and active lives with appropriate support. Early intervention, multidisciplinary care, and advances in assistive technology have significantly improved quality of life and life expectancy for many forms of the condition.

From an educational perspective, understanding MD means recognising that cognitive and learning challenges can accompany certain types – particularly DMD – and that accommodations in academic settings are not just helpful, they are often essential. Awareness of the condition’s physical, emotional, and cognitive dimensions allows educators, support staff, and peers to respond with the right kind of understanding and practical assistance.

What do you think? Given that muscular dystrophy can present very differently even among people with the same type, how should educators and support professionals adapt their approach for each individual rather than applying a one-size-fits-all strategy? And as gene therapies continue to advance, what ethical considerations should guide decisions about access, cost, and who qualifies for these treatments?

References

1. https://www.cdc.gov/muscular-dystrophy/about/index.html
2. https://www.ninds.nih.gov/health-information/disorders/muscular-dystrophy
3. https://www.mayoclinic.org/diseases-conditions/muscular-dystrophy/symptoms-causes/syc-20375388
4. https://www.nichd.nih.gov/health/topics/musculardys/conditioninfo/causes
5. https://medlineplus.gov/genetics/condition/duchenne-and-becker-muscular-dystrophy/
6. https://www.cdc.gov/muscular-dystrophy/types/index.html
7. https://www.hopkinsmedicine.org/news/articles/2024/10/new-gene-therapy-for-duchenne-muscular-dystrophy
8. https://www.ncbi.nlm.nih.gov/books/NBK560582/
9. https://pmc.ncbi.nlm.nih.gov/articles/PMC12182630/
10. https://www.fda.gov/news-events/press-announcements/fda-expands-approval-gene-therapy-patients-duchenne-muscular-dystrophy
11. https://www.mda.org/disease/duchenne-muscular-dystrophy/research